Two-stage design Regulatory [Two-Stage / GS Designs]

posted by Mikkabel – Belgium, 2020-06-23 17:42 (825 d 07:36 ago) – Posting: # 21567
Views: 1,423

Dear all,

I would be pleased to get your advice on the following. We are planning to conduct a pharmacokinetic with adaptive design (two-stage design). Following the lectures from Helmut and the recommendations from the EMA, we decided to use the method B described by Potvin as the study will be performed in EU country.

However, we have some questions regarding the regulatory procedure that should be followed for such a study. Indeed, the stage I will be submitted following a standard CT application including the number of subjects that will be included in the stage I. But what about the stage II? Do we have to notify the CA/EC with the number of subjects to be included in the stage II according to the results obtained after stage I?
Or can we define in the study protocol a maximum number of subjects that will be allowed to participate in the study (stage I + stage II)?

Furthermore, in this two-stage study, we would like to assess the biovailability of two treatment tests (two different formulations) versus a reference treatment. Could you please advice if it is acceptable to perform a two-stage design study with 3 treatments?

Thanks in advance for your feedback,
Kind regards,

Complete thread:

UA Flag
Activity
 Admin contact
22,390 posts in 4,685 threads, 1,594 registered users;
online 14 (0 registered, 14 guests [including 6 identified bots]).
Forum time: Tuesday 01:18 CEST (Europe/Vienna)

Statistics. A sort of elementary form of mathematics which consists of
adding things together and occasionally squaring them.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5